BioCardia, Inc.

Snapshot

BioCardia is a clinical-stage biotech with no revenue and a history of significant losses. The company lost $8.2 million in FY 2025 and burned $7.4 million in operating cash flow, leaving it with just $2.5 million in cash against a $13.5 million market cap. This cash position was effectively exhausted by the time of the latest report, creating a negative cash runway. The share count has more than doubled over the last year, rising 143% to 6.7 million shares, which is a classic sign of dilution used to fund operations.

What's Happening Right Now

• Mon 8th Jun '26 · Financing: BioCardia announced a $4.4 million equity raise on June 8, 2026, which management says extends the cash runway into the first quarter of 2027.
• Fri 5th Jun '26 · Regulatory Update: The FDA confirmed on June 5, 2026, that data from the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval for the cell therapy system.
• Thu 28th May '26 · Regulatory Update: Japan's PMDA issued a Consultation Record on May 28, 2026, supporting the regulatory submission for CardiAMP, with a planned approval submission in Q4 2026.
• Thu 21st May '26 · Clinical Data: Positive trial results presented at EuroPCR on May 21, 2026, showed durable improvements in exercise tolerance and reduced angina episodes for patients.
• Fri 15th May '26 · Earnings & Risk: Q1 2026 results on May 15, 2026, revealed a net loss of $2.26 million and cash reserves of only $951,000, triggering a Nasdaq delisting notice for failing equity requirements.